

Subject: Launch Package: LinkSPINE \$20M Private Placement

From: Martin Zeman <[REDACTED]>

Date: Tue, 24 Jul 2018 09:32:24 -0400

To: "Paul Barrett ([REDACTED])" <[REDACTED]>

Cc: Stewart Oldfield <[REDACTED]>,
Zack Tax <[REDACTED]>,
Oliver Rothauser <[REDACTED]>

Paul,

This comes from our "private markets desk" – you met Oliver end of last year around lunch at Dan's club.

Do you think Jeffrey would be interested?

A \$20 million private placement we are engaged on with our Investment Bank for a medical device company, LinkSPINE. LinkSPINE is targeting the outpatient market for spinal surgery with two products: 1) a novel, minimally invasive midline kit providing physicians procedural flexibility and efficiency which is specifically designed for use in outpatient facilities 2) TargetLINK, a chip-based navigation software platform to facilitate the placement of screws while reducing radiation exposure to physicians and patients during surgery by 80-90%.

The Company's consumable products are already FDA approved for commercial use and the Company expects their TargetLINK product to receive FDA approval in the next 9 months.

The Company has been incubated by the Link Group, a German based orthopedics firm with an established track record of successfully bringing medical device products to market. To date, they have invested \$25 million into LinkSPINE.

Use of proceeds for this round are being allocated to build a robust

commercial sales and marketing infrastructure for their products.

Attached you can find a brief teaser on the Company and if you are interested in learning more we are able to facilitate an introductory call with our Investment Bank to take a deeper dive into both the products and spinal surgery market.

Martin

{cid:image001.gif@01D259D5.3E2DF0F0}

Martin Zeman
Director | Key Client Partners

Deutsche Bank Wealth Management
DB Securities Inc

345 Park Avenue, 10154-0004 New York, NY, USA
Tel. [REDACTED]
Mobile [REDACTED]
Email [REDACTED]

KCP products and services are intended and available only for persons who are sophisticated institutional investors within the meaning of the FINRA Rule 4512(C)(3), and who are capable of evaluating the strategies, characteristics and investment risks of, and exercising independent judgment in evaluating, the ideas and products discussed herein. Trades and transactions are subject to relevant internal approvals of DBSI or its affiliates prior to execution, and the execution of any transaction or idea discussed herein is conditional on your becoming a client of Deutsche Bank. Key Client Partners (KCP) products, investment ideas and solutions and related matters discussed herein are provided for discussion purposes only, and strictly on a non-advisory basis. The KCP Americas desk does not provide investment advice. The information set forth herein is confidential and personal to you and is being presented for your information and for discussion purposes only. Any reproduction and/or redistribution thereof (in whole or in part) or disclosure of its content without our written consent is strictly forbidden. This communication does not create any legally binding obligation on the part of DBSI or any of its affiliates.

This communication may contain confidential and/or privileged information. If you are not the intended recipient (or have received this communication in error) please notify the sender immediately and destroy this communication. Any unauthorized copying, disclosure or distribution of the material in this communication is strictly forbidden.

Please refer to <https://db.com/disclosures> for additional EU corporate and regulatory disclosures.

Deutsche Bank does not render legal or tax advice, and the information contained in this communication should not be regarded as such.